Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02394535 · ClinicalTrials.gov registry record · Phase 1
Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT02394535: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT02394535 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02394535, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of nab-paclitaxel when given together with capecitabine and radiation therapy following first treatment with chemotherapy (induction therapy) in treating patients with pancreatic cancer that is not spread to tissue far away but is not operable due to abutment or encasement of blood vessels nearby (locally advanced). Drugs used in chemotherapy, such as nab-paclitaxel and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving nab-paclitaxel, capecitabine, and radiation therapy together may kill more tumor cells.
Interventions
- DRUG Capecitabine
- OTHER Laboratory Biomarker Analysis
- OTHER Questionnaire Administration
- RADIATION Radiation Therapy
- DRUG Nab-paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2015-11-12 |
| Est. Completion | 2022-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02394535
The ClinicalTrials.gov registry entry for NCT02394535 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Capecitabine is the first listed.
NCT02394535 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02394535 about?
NCT02394535 is a clinical study titled "Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer". This phase I trial studies the side effects and best dose of nab-paclitaxel when given together with capecitabine and radiation therapy following first treatment with chemotherapy (induction therapy) in treating patients with pancreatic cancer that is not spread to tissue far away but is not operabl...
What is the current status of trial NCT02394535?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2015-11-12. Estimated completion is 2022-08-31.
What interventions are being tested in trial NCT02394535?
The interventions under investigation include: Capecitabine (DRUG), Laboratory Biomarker Analysis (OTHER), Questionnaire Administration (OTHER), Radiation Therapy (RADIATION), Nab-paclitaxel (DRUG).
Who is sponsoring clinical trial NCT02394535?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.